Antiretroviral Agent: Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) with potent antiviral activity against the Human Immunodeficiency Virus Type 1 (HIV-1).
Standard Adult Dosage: The 600 mg tablet is the standard once-daily dose for adults and adolescents weighing at least 40 kg.
Combination Therapy Component: It is a foundational component of combination antiretroviral therapy (cART) and must always be used in combination with at least two other antiretroviral agents to prevent the development of viral resistance.
Film-Coated Tablet: The tablet is film-coated for oral administration. It should be swallowed whole and not be crushed, broken, or chewed.
Advantages
Once-Daily Dosing: The long half-life of Efavirenz allows for once-daily dosing, which simplifies the treatment regimen and significantly improves patient adherence.
High Efficacy: When used as part of a cART regimen, Efavirenz is highly effective at suppressing HIV viral replication, reducing viral load to undetectable levels, and improving immune function.
Well-Established: Efavirenz has been a cornerstone of global HIV treatment for many years, with a vast body of clinical data supporting its efficacy and safety profile.
Potent Component: It is a powerful and reliable component of many first-line ART regimens, often included in fixed-dose combinations with other drugs.
Uses
HIV-1 Infection: The primary indication is for the treatment of HIV-1 infection in adults and adolescents weighing at least 40 kg, as part of a combination regimen. It is not active against HIV-2.
First-Line Therapy: It has been a recommended component of first-line antiretroviral therapy in many international guidelines, particularly in resource-limited settings.
Post-Exposure Prophylaxis (PEP): It can be used as a component of PEP regimens to prevent HIV infection following a potential exposure.
Fixed-Dose Combinations: The 600 mg dose is a key ingredient in several fixed-dose combination tablets that include other antiretroviral drugs, further simplifying treatment.
Nature
NNRTI Class: Efavirenz belongs to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class of drugs.
Mechanism of Action: Efavirenz works by binding directly to a specific site on the HIV-1 reverse transcriptase enzyme. This non-competitive binding causes a conformational change that inactivates the enzyme and blocks the synthesis of viral DNA.
Inhibition of Viral Replication: By halting the conversion of HIV’s RNA genome into DNA, Efavirenz prevents a crucial step in the viral replication cycle, thereby suppressing viral activity in the body.
Metabolism & Side Effects: Efavirenz is primarily metabolized by liver enzymes and can cause central nervous system (CNS) side effects like dizziness, abnormal dreams, and insomnia. These effects can be mitigated by taking the medication on an empty stomach at bedtime.
Storage
Temperature: Store Efavirenz tablets at a controlled room temperature, typically between 20∘C to 25∘C (68∘F to 77∘F).
Protection: Keep the tablets in their original, tightly closed container, protected from light and moisture.
Administration: The medication should be taken on an empty stomach, preferably at bedtime, to reduce the frequency and intensity of CNS side effects.
Patient Warning: Patients must be educated on the importance of not skipping doses to prevent the development of viral resistance. It is also important to use a reliable method of contraception due to potential for fetal harm.
